Scinai Immunotherapeutics Ltd. current report, Q3 FY2016

Vollständiges Dokument

Business Context and Reporting Period

This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) is dated September 20, 2016. The report announces the rescheduling of the Company's Annual General Meeting of Shareholders from September 22, 2016, to September 29, 2016, to allow shareholders additional time to consider agenda amendments.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice and does not contain financial statements or performance metrics.

Material Changes

The primary material change is the rescheduling of the Annual General Meeting. Additionally, the filing details the final agenda for the meeting, which includes:

  • Reelection of Ms. Michal Marom Brikman and election of Dr. Ruth Ben Yakar as independent directors.
  • Approval of indemnification agreements for the directors.
  • Ratification of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent auditors.
  • Adoption of a new Share Option Plan reserving 6% of issued and outstanding share capital on a fully diluted basis.
  • Extension of the CEO's service agreement for an additional seven years.
  • Election of Mr. Ori Mor as a director.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or discussion of business risks. Management commentary is limited to the Board's recommendation to vote "FOR" proposals 1 through 6. The Board offered no recommendation regarding proposal 7 (election of Mr. Ori Mor) as it was not discussed by the Board. Voting procedures for TASE shares and NASDAQ ADS holders were clarified.

Key Facts for Investor Verification

  • Verify the new meeting date of September 29, 2016, at 4:00 pm Israel time.
  • Confirm the Board's recommendation to approve the 6% share reservation for the new Option Plan.
  • Note the lack of Board recommendation for the election of Mr. Ori Mor.
  • Check the specific voting mechanisms for TASE shareholders versus ADS holders on NASDAQ.